EFFICACY OF PROBIOTICS IN HELICOBACTER PYLORI ERADICATION THERAPY
Session
Medicine and Nursing
Description
INTRODUCTION: Development of antibiotic resistance, maladaptation of patients to receiving eradication therapy, side effects of drugs are the main factors influencing the apparent decrease in eradication rates of Helicobacter pylori (H. pylori). In our work on classical eradication therapy of H. pylori, we have added probiotics and evaluated their role in eradication, as well as tried to evaluate the role of probiotics in reducing the occurrence of side effects of antibiotics.
METHODS: The study included 114 patients in most cases with dyspeptic complaints and H. pylori from the Gastroenterology Clinic of HUCSK, and the Specialist Clinic " Gastromed -AFM " in Pristina. The patients were divided into two groups. The first group consisted of 62 patients, who were given the classical therapy with pantoprazole 40 mg, twice a day for half an hour before a meal, amoxicillin 1 g, twice a day after a meal for two weeks, and clarithromycin 500 mg, 2 times a day after meals, for two weeks. The second group consisted of 53 patients, to whom the probiotics Lactobacillus reuteri were added to the classical eradication therapy as well as the combination of three other probiotics Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium lactis, in the form of 3 capsules of Helicobalans, for two weeks. One month after the end of therapy, the condition of H. pylori was assessed with antigen in the feces, urease test, or histopathological analysis. Where H. pylori were negative it was accepted that eradication was successfully performed.
RESULTS: H. pylori eradication was achieved in 38 of 62 patients in the first group (61,3%), and in 37 of the 53 patients in the second group (69,8%). Although the eradication rate in the second group was higher, the statistical difference between the two groups was not statistically significant (p = 0.199). Regarding the side effects of prescribed therapies, the first group had side effects in 27 (43.5%) patients, while the second group with probiotics in 17 (32%) patients. However, in terms of the occurrence of side effects from the use of ordinary therapy, there was no statistical difference between these two groups (p = 0.194).
CONCLUSIONS: The addition of probiotics to classical H. pylori eradication therapy can reduce the side effects of therapeutic regimens as well as increase the success of H. pylori eradication. There is a need for prospective and randomized work with a larger number of patients.
Keywords:
probiotics, H. pylori, Kosovo
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-550-47-5
Location
UBT Kampus, Lipjan
Start Date
30-10-2021 12:00 AM
End Date
30-10-2021 12:00 AM
DOI
10.33107/ubt-ic.2021.179
Recommended Citation
Skender, Telaku; Mimoza, Telaku; Emir, Behluli; and Hajrullah, Fejza, "EFFICACY OF PROBIOTICS IN HELICOBACTER PYLORI ERADICATION THERAPY" (2021). UBT International Conference. 111.
https://knowledgecenter.ubt-uni.net/conference/2021UBTIC/all-events/111
EFFICACY OF PROBIOTICS IN HELICOBACTER PYLORI ERADICATION THERAPY
UBT Kampus, Lipjan
INTRODUCTION: Development of antibiotic resistance, maladaptation of patients to receiving eradication therapy, side effects of drugs are the main factors influencing the apparent decrease in eradication rates of Helicobacter pylori (H. pylori). In our work on classical eradication therapy of H. pylori, we have added probiotics and evaluated their role in eradication, as well as tried to evaluate the role of probiotics in reducing the occurrence of side effects of antibiotics.
METHODS: The study included 114 patients in most cases with dyspeptic complaints and H. pylori from the Gastroenterology Clinic of HUCSK, and the Specialist Clinic " Gastromed -AFM " in Pristina. The patients were divided into two groups. The first group consisted of 62 patients, who were given the classical therapy with pantoprazole 40 mg, twice a day for half an hour before a meal, amoxicillin 1 g, twice a day after a meal for two weeks, and clarithromycin 500 mg, 2 times a day after meals, for two weeks. The second group consisted of 53 patients, to whom the probiotics Lactobacillus reuteri were added to the classical eradication therapy as well as the combination of three other probiotics Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium lactis, in the form of 3 capsules of Helicobalans, for two weeks. One month after the end of therapy, the condition of H. pylori was assessed with antigen in the feces, urease test, or histopathological analysis. Where H. pylori were negative it was accepted that eradication was successfully performed.
RESULTS: H. pylori eradication was achieved in 38 of 62 patients in the first group (61,3%), and in 37 of the 53 patients in the second group (69,8%). Although the eradication rate in the second group was higher, the statistical difference between the two groups was not statistically significant (p = 0.199). Regarding the side effects of prescribed therapies, the first group had side effects in 27 (43.5%) patients, while the second group with probiotics in 17 (32%) patients. However, in terms of the occurrence of side effects from the use of ordinary therapy, there was no statistical difference between these two groups (p = 0.194).
CONCLUSIONS: The addition of probiotics to classical H. pylori eradication therapy can reduce the side effects of therapeutic regimens as well as increase the success of H. pylori eradication. There is a need for prospective and randomized work with a larger number of patients.